PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer  Mathilde.

Slides:



Advertisements
Similar presentations
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.
Advertisements

Detection of Abdominal Aortic Aneurysm in Patients with Peripheral Artery Disease A. Barba, L. Estallo, L. Rodríguez, M. Baquer, M. Vega de Céniga European.
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Preoperative Evaluations: The Very Last Chance To Identify a Problem With a Pacemaker or Implanted Cardioverter-Defibrillator Marc A. Rozner, PhD, MD Journal.
Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /
Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)
Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease Yava L. Jones-Hall, Matthew B.
Breast Cancer Advocacy across Europe through the work and development of EUROPA DONNA, the European Breast Cancer Coalition  M. Buchanan, S. Kyriakides,
Volume 15, Issue 3, Pages (March 2014)
European Journal of Cancer
Leen Verleye, Petronella B. Ottevanger, Gunnar B
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children.
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase.
Volume 17, Issue 5, Pages (May 2016)
European Journal of Cancer
Nicoletta Colombo, Martin Gore 
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)  Axel.
Rare cancers of the head and neck area in Europe
Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit  Pim J. van Leeuwen, David Connolly, Anna.
European Journal of Cancer
Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1–3 brain metastases: Results.
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating.
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind.
The feasibility of nipple aspiration and duct lavage to evaluate the breast duct epithelium of women with increased breast cancer risk  Dominique Twelves,
Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic.
Managing Metastatic Bone Pain: The Role of Bisphosphonates
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric.
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study.
Whole-body diffusion-weighted magnetic resonance imaging: Current evidence in oncology and potential role in colorectal cancer staging  Doenja M.J. Lambregts,
The benefits and harms of breast cancer screening
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria  M. Tazdait,
Managing Metastatic Bone Pain: The Role of Bisphosphonates
Volume 73, Issue 4, Pages (April 2018)
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus  T. Bärnighausen, D.E. Bloom, E.T. Cafiero,
Volume 9, Issue 12, Pages (December 2008)
Volume 43, Issue 4, Pages (April 2003)
CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype  Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
International Journal of Surgery
Screening for colorectal, breast, and cervical cancer in the elderly: A review of the evidence  Louise C. Walter, MD, Carmen L. Lewis, MD, MPH, Mary B.
Palliative Neck Surgery in Metastatic Lung Cancer: A Case Report
Volume 10, Issue 6, Pages (June 2009)
Practice Notes from the AAAI
New Views into the Genetic Landscape of Metastatic Breast Cancer
Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen  Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.
Antje Timmer*, Lloyd R. Sutherland*,‡, Francois Martin§ 
Vector control: a cornerstone in the malaria elimination campaign
The pregnancy associated protein glycodelin as a follow-up biomarker in a male non- small cell lung cancer patient  Marc A. Schneider, Nicolas C. Kahn,
Metastatic Breast Cancer Causing Gas Gangrene
New HCV therapies on the horizon
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.
Long-Term Hormonal Therapy: Who Would Benefit?
Nicholas D. James, Jim W. Growcott  European Urology Supplements 
Confessions of a journal junkie
European Urology is “Your” Journal
News & Notes Journal of Allergy and Clinical Immunology
Erratum Journal of Thoracic Oncology
Arlene Chan, Marc Buyse, Bin Yao  The Lancet Oncology 
Gender differences in irritable bowel syndrome
Are we losing the fight against malaria one more time?
Oncoforum Urology: Prostate Cancer 2008 at a Glance
New patterns of HIV-1 resistance during HAART
D.A. Robinson, M.C. Enright  Clinical Microbiology and Infection 
Role of glucocorticoids in acidosis
News Beyond Our Pages Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Presentation transcript:

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer  Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, Jihane Pakradouni, Magali Provansal, Jacques Camerlo, Renaud Sabatier, François Bertucci, Emmanuelle Charafe-Jauffret, Alice Hervieu, Jean-Marc Extra, Patrice Viens, François Lokiec, Jean-Marie Boher, Anthony Gonçalves  European Journal of Cancer  Volume 86, Pages 28-36 (November 2017) DOI: 10.1016/j.ejca.2017.08.025 Copyright © 2017 Elsevier Ltd Terms and Conditions

Fig. 1 Dose escalation schedule. European Journal of Cancer 2017 86, 28-36DOI: (10.1016/j.ejca.2017.08.025) Copyright © 2017 Elsevier Ltd Terms and Conditions

Fig. 2 Complete response after two cycles of buparlisib 80 mg–lapatinib 1250 mg. A 45-year-old women with HER2-positive, oestrogen receptor–positive inflammatory breast cancer with second metastatic relapse (ovarian and retroperitoneal relapse) was enrolled in PIKHER2 study on November 2014 (left panel) and received buparlisib 80 mg plus lapatinib 1250 mg once daily. After two cycles (right panel), she reached complete remission. Arrow indicates initial metastatic lymph nodes (left panel) and their disappearance (right panel). European Journal of Cancer 2017 86, 28-36DOI: (10.1016/j.ejca.2017.08.025) Copyright © 2017 Elsevier Ltd Terms and Conditions

Fig. 3 Clinical benefit rate according to PIK3CA genotype and hormone receptor expression. (A) Clinical benefit rate (objective response and/or stable disease for at least 24 weeks) according to PIK3CA mutational status, as determined by Sanger sequencing on archival or freshly obtained metastatic tissue. (B) Clinical benefit rate according to expression of hormone receptors on metastatic tissue. European Journal of Cancer 2017 86, 28-36DOI: (10.1016/j.ejca.2017.08.025) Copyright © 2017 Elsevier Ltd Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.